Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a tiny dose of naltrexone beat long-COVID fatigue?

NCT ID NCT05430152

First seen Apr 04, 2026 · Last updated May 19, 2026 · Updated 6 times

Summary

This study tested whether a low dose of the drug naltrexone (LDN) can help reduce fatigue, pain, and other symptoms in people with Post-COVID fatigue syndrome. 160 adults who had COVID-19 at least 3 months earlier took either LDN or a placebo for several weeks. The goal was to see if LDN improves energy, activity levels, and quality of life, and if it lowers inflammation in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POST-VIRAL FATIGUE SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Women's Health Research Institute

    Vancouver, British Columbia, V6H 3N1, Canada

Conditions

Explore the condition pages connected to this study.